The November issue of Squire Patton Boggs Bio/Pharma Beat is now available. Our monthly newsletter reports on important patent law developments in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month’s issue covers relevant news from October 2019, including:
- The Federal Circuit holds the “hope” that a potentially promising drug will treat a particular cancer is not enough to establish a reasonable expectation of success
- The Federal Circuit holds a method of treating hepatitis C with a genus of compounds invalid for lack of enablement and written description
- California enacts a “pay for delay” law
It was recently reported that 
The European Commission recently published a 
Steven Auvil, partner and leader of our US IP litigation practice will serve as a moderator at IAM’s Patent Litigation: Navigating the Law and Policy Landscape in the U.S., on November 5th in Washington DC.
As 
Consistency and repetition are important in building a brand. Or are they? The digital economy is evolving so quickly that it has pushed brand owners to challenge trademark fundamentals by adopting trademarks that evolve as well. Proponents of such shifting trademarks, called “fluid” marks, believe that they attract the attention of potential consumers, increase brand awareness and maintain the interest of existing consumers in an accelerated marketplace. Beyond the occasional update that a brand owner might traditionally make, say, every decade, a fluid mark changes regularly, even every day. But fluid trademarks, although becoming more prevalent, create particular risks for the brand owner. 